Evofem Biosciences Posts $2.63 Million in Q2 2026 Net Product Sales

Evofem Biosciences, Inc. recorded $2.633 million in Q2 2026 net product sales, while management raised substantial doubt about its ability to continue as a going concern.

The three-month period ended June 30, 2026. Evofem's net loss attributable to common stockholders was $11.144 million, and its basic and diluted loss per share was $0.08. The company filed its Form 10-Q on Aug. 14, 2026.

At June 30, Evofem had $285,000 in restricted cash and cash equivalents. Management said cash and cash equivalents were insufficient to fund operations for at least 12 months, and the circumstances raised substantial doubt about the company's ability to continue as a going concern.